Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
View original at globenewswire.comCrescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestina…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Development strategy combining ASCEND and planned ADC combination studies is intended to rapidly expand understanding of CR-001 across multiple solid tumor types, beginning with initial data expected in Q1 2027
60% confidenceProof-of-concept clinical data from ASCEND including initial safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity from dose escalation and backfill cohorts anticipated in Q1 2027
60% confidenceCR-001 is designed to serve as an immuno-oncology backbone and best-in-class PD-1 x VEGF bispecific antibody for people living with cancer
60% confidenceThe first Phase 1/2 ADC combination trial with CR-001 is expected to initiate in the second half of 2026
60% confidenceStrong global investigator engagement in ASCEND underscores the unmet need in cancer treatment and the study's efficient design to evaluate CR-001 as monotherapy and in combination with standard-of-care therapies
60% confidenceInitial data from Phase 1/2 trial in China of CR-001 in combination with a Kelun-Biotech ADC anticipated in mid-2027 (Q2/Q3)
60% confidenceIn preclinical studies, CR-001 demonstrated cooperative pharmacology with increased binding to PD-1 and signal blockade in the presence of VEGF, as well as robust antitumor activity
60% confidenceInitial data of CR-001 in combination with standard of care chemotherapy from ASCEND dose expansion cohorts anticipated in mid-2027 (Q2/Q3)
60% confidenceKelun-Biotech plans to initiate a Phase 1/2 trial of CR-001 (SKB118) in China in the first half of 2026
60% confidenceASCEND trial is expected to enroll up to 290 patients across dose-escalation, backfill, and dose-optimization cohorts at centers in the United States, Europe, and Asia Pacific
60% confidenceCR-001's anti-VEGF activity may normalize the vasculature at the tumor site, potentially improving the localization and effectiveness of combination therapies such as ADCs
60% confidence